A phase 2 randomized, double-blind, placebo-controlled, dose-ranging trial (ARGON-1) has shown that when administered to non-cirrhotic biopsy-proven NASH patients, a 12-week course of EDP305 reduced liver fat content and decreased ALT [56]. Here, GPT is linked to metabolic dysfunction-associated steatohepatitis.